Good news: You told us what you want, and we have worked diligently to make it happen.Better news: The 14th Annual Immunogenicity for Biotherapeutics event will be the best yet!
You gave us specific feedback and we took it to heart. There are many refinements to the Immunogenicity for Biotherapeutics conference that will enhance your event experience and make you glad you attend including:
- - No selling from the podium. Our sponsors and service providers are valued members of the Immunogenicity event community. We have worked closely with them to ensure that you walk away with enhanced value and insight from their presentations.
- - Reliable Agenda. We want to deliver the program that you expect and demand. We have worked tirelessly with our speakers to confirm their presentations and are confident that the program you want to hear will be the one you experience.
- - Enhanced venue. The new layout for the lecture hall and sessions is optimized so you can hear and see better, and enjoy all aspects of the event.
- - Compelling line-up of keynote speakers, detailing how best to predict and measure the fate of biomolecules in-vivo and contrasting in-vivo measurements with benchmarks that had been set in-vitro including Jack Ragheb, Senior Regulatory Research Officer, CDER, FDA, Amy Rosenberg, Director Division of Therapeutic Proteins, FDA and Daniela Verthelyi, Chief, Laboratory of Immunology, FDA
To learn more about our new and improved event, download the full agenda here.
The Immunogenicity for Biotherapeutics Conference is taking place March 18-20, 2013, in Baltimore, MD. As a reader of this blog, you receive an exclusive discount of 15% off the standard rate when you register using code XP1838Link. If you have any questions about the agenda, feel free to contact Jennifer Pereira.
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment